Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Links shared publicly online about this topic.

  • 860
    total visits

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

news-medical.net —

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.

View full resource at news-medical.net

Tags: Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Type 2 Diabetes, Amaryl, Oncology, News

  • Share

Most Recently Shared on September 20, 2010 at 3:21 pm By:

Oncology_News News-Medical.Net

Oncology News: Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients: Bristol... http://bit.ly/dCoWs7

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

News-Medical.Net News-Medical.Net

Investigational Drug Dapagliflozin For Diabetes Meets Study Goals After 24-Week Phase 3 Study - QualityPoint Technologies

qualitypointtech.net — “Dapagliflozin when added to existing glimepiride (sulphonylurea) therapy significantly reduced HbA1C (glycosylated hemoglobin) in adults with Type 2 Diabetes, compared to patients taking glimepiride plus a placebo, a 24-week Phase 3 Study revealed. In a joint announcement, Astra Zeneca PLC. and Bristol-Myers Squibb Company said the trial met the study goals...” View full resource at qualitypointtech.net

  • View Related
  • Share

Most Recently Shared on September 21, 2010 at 6:25 am By:

MedicalFeed MedicalFeed Health News Feed

Investigational Drug Dapagliflozin For Diabetes Meets Study Goals After 24-Week Phase 3 Study: Dapagliflozin when ... http://bit.ly/aWAV4S

2 years ago...

Reply

Retweet

Favorite

Advertisement